Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva: A systematic review and meta-analysis

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tibolone and risk of gynecological hormone sensitive cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Does HPV status influence survival after vulvar cancer?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Human papillomavirus vaccination in immigrants and descendants of immigrants in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

In this updated systematic review and meta-analysis we estimate the pooled prevalence of human papillomavirus (HPV) DNA and HPV type distribution in squamous cell carcinoma of the vulva (vulvar cancer) and vulvar intraepithelial neoplasia (VIN). PubMed, Embase, and Cochrane Library databases were used to identify studies published between 1990 and 2015 and using a PCR-based or hybrid capture test to evaluate the presence of HPV DNA in vulvar cancer or VIN. Pooled estimates of the HPV prevalence with corresponding 95% confidence intervals (CI) were calculated based on a random effects model. The I(2) statistic was used to describe the amount of heterogeneity. In meta-regression analyses potential sources of heterogeneity were evaluated. We identified 92 eligible papers, comprising altogether 5015 cases of vulvar cancer (64 papers) and 2764 cases of VIN (48 papers). The pooled prevalence of HPV in vulvar cancer was 39.7% (95% CI: 35.1-44.4%). Overall, 76.3% (95% CI: 70.1-82.1%) of VIN lesions tested HPV-positive, while the HPV prevalence in new subcategories of VIN, uVIN and dVIN, was 86.2% (95% CI: 73.5-95.5%) and 2.0% (95% CI: 0-10.0%), respectively. Substantial between-study heterogeneity was observed (vulvar cancer: I(2) = 88.4%; VIN: I(2) = 90.7%) with the largest variation between geographical regions. Among HPV-positive cases the predominant high-risk HPV type was HPV16, followed by HPV33 and HPV18. HPV6 was detected as a single infection in a small subset of VIN and vulvar cancer samples. Thus, HPV vaccination targeting these HPV types may prevent a substantial number of vulvar lesions. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalRadiation Oncology Investigations
Volume141
Issue number6
Pages (from-to)1161–1169
ISSN0020-7136
DOIs
Publication statusPublished - Sep 2017

    Research areas

  • Journal Article

ID: 50607560